CD40 and neoplasm: Emerging evidence suggests that activating neutrophils has therapeutic effects in tumor immunotherapy, including the Bacillus Calmette-Guérin (BCG), β-glucan, or a combination therapy involving anti-CD40 antibodies, TNF-α, and tumor-binding antibodies (12–14).